Zum Inhalt springen
Home » Aummune’s Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003

Aummune’s Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003

Aummune, a clinical-stage biopharmaceutical company developing a unique class of oligonucleotide drugs to treat solid tumors, announced today that an abstract of the Company’s Phase 1 trial of its proprietary, investigational product AM003 will be presented on June 1, 2024, at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) taking place in Chicago, Illinois.

Aummune’s Poster at ASCO 2024 to Highlight Ongoing Phase 1 Trial for AM003